INSM
Price
$70.02
Change
-$3.83 (-5.19%)
Updated
Dec 18, 04:59 PM (EDT)
64 days until earnings call
NWPHF
Price
$9.36
Change
-$2.64 (-22.00%)
Updated
Sep 9 closing price
Ad is loading...

INSM vs NWPHF

Header iconINSM vs NWPHF Comparison
Open Charts INSM vs NWPHFBanner chart's image
Insmed
Price$70.02
Change-$3.83 (-5.19%)
Volume$43.1K
CapitalizationN/A
Newron Pharmaceuticals SPA
Price$9.36
Change-$2.64 (-22.00%)
Volume$500
CapitalizationN/A
INSM vs NWPHF Comparison Chart
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INSM vs. NWPHF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and NWPHF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (INSM: $73.85 vs. NWPHF: $9.36)
Brand notoriety: INSM and NWPHF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 149% vs. NWPHF: 100%
Market capitalization -- INSM: $13.21B vs. NWPHF: $176.38M
INSM [@Biotechnology] is valued at $13.21B. NWPHF’s [@Biotechnology] market capitalization is $176.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileNWPHF’s FA Score has 0 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • NWPHF’s FA Score: 0 green, 5 red.
According to our system of comparison, INSM is a better buy in the long-term than NWPHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 5 TA indicator(s) are bullish.

  • INSM’s TA Score: 5 bullish, 3 bearish.

Price Growth

INSM (@Biotechnology) experienced а +1.69% price change this week, while NWPHF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.

Reported Earning Dates

INSM is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($13.2B) has a higher market cap than NWPHF($176M). INSM YTD gains are higher at: 138.303 vs. NWPHF (79.310).
INSMNWPHFINSM / NWPHF
Capitalization13.2B176M7,500%
EBITDA-769.56MN/A-
Gain YTD138.30379.310174%
P/E RatioN/AN/A-
Revenue343MN/A-
Total Cash1.47BN/A-
Total Debt1BN/A-
FUNDAMENTALS RATINGS
INSM vs NWPHF: Fundamental Ratings
INSM
NWPHF
OUTLOOK RATING
1..100
6942
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
1561
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3953
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NWPHF's Valuation (71) in the null industry is in the same range as INSM (82) in the Biotechnology industry. This means that NWPHF’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (15) in the Biotechnology industry is somewhat better than the same rating for NWPHF (61) in the null industry. This means that INSM’s stock grew somewhat faster than NWPHF’s over the last 12 months.

INSM's SMR Rating (100) in the Biotechnology industry is in the same range as NWPHF (100) in the null industry. This means that INSM’s stock grew similarly to NWPHF’s over the last 12 months.

INSM's Price Growth Rating (39) in the Biotechnology industry is in the same range as NWPHF (53) in the null industry. This means that INSM’s stock grew similarly to NWPHF’s over the last 12 months.

INSM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NWPHF (100) in the null industry. This means that INSM’s stock grew similarly to NWPHF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSM
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Declines
ODDS (%)
Bearish Trend 6 days ago
74%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with NOXOF. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then NOXOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+0.63%
NOXOF - INSM
88%
Closely correlated
N/A
THAR - INSM
76%
Closely correlated
+0.46%
NWPHF - INSM
49%
Loosely correlated
N/A
AGIO - INSM
41%
Loosely correlated
-1.71%
ARCT - INSM
39%
Loosely correlated
-3.14%
More

NWPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NWPHF has been loosely correlated with NOXOF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NWPHF jumps, then NOXOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NWPHF
1D Price
Change %
NWPHF100%
N/A
NOXOF - NWPHF
55%
Loosely correlated
N/A
INSM - NWPHF
49%
Loosely correlated
+0.63%
SGMT - NWPHF
35%
Loosely correlated
+3.66%
MMIRF - NWPHF
30%
Poorly correlated
N/A
BLPH - NWPHF
21%
Poorly correlated
N/A
More